Pyxis Oncology, Inc. — Director's Dealing 2023

Sep 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2023-09-11

Reporting Person: Sullivan Lara (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-11	Common Stock	S	20000	$2.2707	Disposed	2605182	Direct
2023-09-12	Common Stock	S	4917	$2.2516	Disposed	2600265	Direct
2023-09-13	Common Stock	S	3000	$2.2719	Disposed	2597265	Direct
2023-09-13	Common Stock	F	184742	$2.13	Disposed	2412523	Direct

Footnotes

F1: Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4.

F2: The transaction was executed in multiple trades in prices ranging from $2.13 to $2.36.

F3: The transaction was executed in multiple trades in prices ranging from $2.21 to $2.30.

F4: The transaction was executed in multiple trades in prices ranging from $2.25 to $2.34.

F5: Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units.